Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Proc Natl Acad Sci USA 100:30773082
We focus on providing the highest quality ingredients so that you can feel confident you are doing something meaningful for your body, even on your busiest days
Our compounded Tirzepatide with L-Carnitine formulation is designed to enhance metabolic efficiency, improve energy utilization, and support sustainable weight loss and body composition goals
Mensa3 AASLD: Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-nave Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis - (10/23/17) IAS: Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17) IAS: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17) IAS: Maviret /G-P in HIV+ Coinfected / ART DDIs - (09/12/17) EASL: New HCV Drugs at EASL 2017 - (05/09/17) AASLD: Safety and Efficacy of Glecaprevir / Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1 - 6 and Recent Drug Use - (11/27/17) AASLD: Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials - (10/29/17) Abstract This study assessed the efficacy and safety of ribavirin-free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options
US$ 26.61
US$ 26.04
US$ 27.19
